NUNitin Udar

Nitin Udar

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Nitin Udar has a total of 394 co-authors. Here are the top co-authors by number of shared publications:

  • Shari R. Atilano

    Gavin Herbert Eye Institute, University of California Irvine, Irvine, CA 92697, USA

    15 shared publications
  • Maria Cristina Kenney

    Department of Ophthalmology, Gavin Herbert Eye Institute, University of California Irvine, Irvine, CA 92697, USA

    11 shared publications
  • Marilyn Chwa

    Department of Ophthalmology, Gavin Herbert Eye Institute, University of California Irvine, Irvine, CA, USA

    10 shared publications
  • Anthony B. Nesburn

    Gavin Herbert Eye Institute, University of California Irvine, Irvine, CA, United States; Cedars-Sinai Medical Center, Los Angeles, CA, United States

    9 shared publications
  • David S. Boyer

    Retina-Vitreous Associates Medical Group, Beverly Hills, CA, United States

    7 shared publications
  • Douglas C. Wallace

    Center of Mitochondrial and Epigenomic Medicine, The Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA

    7 shared publications

Latest Publications

  • Open Access

    Supplementary Table 1 from Therapeutic Potential of the Poly(ADP-ribose) Polymerase Inhibitor Rucaparib for the Treatment of Sporadic Human Ovarian Cancer

    by Maike Ihnen, Christine zu Eulenburg, Teodora Kolarova, Jing Wei Qi, Kanthinh Manivong, Meenal Chalukya, Judy Dering, Lee Anderson, Charles Ginther, Alexandra Meuter, et al.

  • Open Access

    Supplementary Figures 1 - 6 from Therapeutic Potential of the Poly(ADP-ribose) Polymerase Inhibitor Rucaparib for the Treatment of Sporadic Human Ovarian Cancer

    by Maike Ihnen, Christine zu Eulenburg, Teodora Kolarova, Jing Wei Qi, Kanthinh Manivong, Meenal Chalukya, Judy Dering, Lee Anderson, Charles Ginther, Alexandra Meuter, et al.

    PDF file - 603K, Supplemental Figure S1: Gene maps of the BRCA1 (A) and BRCA2 (B) CpG islands examined with bisulfite pyrosequencing. Supplemental Figure S2: Anchorage independent growth inhibition at 1μM rucaparib in soft agar. Of the 39 tested ovarian cancer cell lines 22 formed colonies in soft agar. Supplemental Figure S3: Microarray hybridizations of the cell line panel were performed using the Agilent Whole Human Genome 4X44K array chip.Supplemental Figure S4: Chemical structures of compounds used for the drug interaction studies.Supplemental Figure S5: A multivariate ANOVA model (accounting for type of chemotherapy, cell line, and drug concentration as single factors) indicates that the drug combination effects differed significantly between individual chemotherapeutic agents (P=0.010). Supplemental Figure S6: A multivariate ANOVA model (accounting for type of chemotherapy, cell line, and drug concentration as single factors) indicates that the best combination effect was achieved at lower topotecan (0.031 μM) and rucaparib (0.625 μM) drug concentrations (P=0.018).

  • Open Access

    Altered Retrograde Signaling Patterns in Breast Cancer Cells Cybrids with H and J Mitochondrial DNA Haplogroups

    by Steven Chang, Lata Singh, Kunal Thaker, Sina Abedi, Mithalesh K. Singh, Tej H. Patel, Marilyn Chwa, Shari R. Atilano, Nitin Udar, Daniela Bota, et al.

    The aim of this study was to determine the role of retrograde signaling (mitochondria to nucleus) in MCF7 breast cancer cells. Therefore, in the present study, MCF7-H and MCF7-J cybrids were produced using the mitochondria from the same H and J individuals that were already used in our non-diseased retinal pigment epithelium (ARPE19) cybrids. MCF7 cybrids were treated with cisplatin and analyzed for cell viability, mitochondrial membrane potential, ROS, and expression levels of genes associated with the cGAS-STING and cancer-related pathways. Results showed that unlike the ARPE19-H and ARPE19-J cybrids, the untreated MCF7-H and MCF7-J cybrids had similar levels of ATP, lactate, and OCR: ECAR ratios. After cisplatin treatment, MCF7-H and MCF7-J cybrids showed similar (a) decreases in cell viability and ROS levels; (b) upregulation of ABCC1, BRCA1 and CDKN1A/P21; and (c) downregulation of EGFR. Cisplatin-treated ARPE19-H and ARPE19-J cybrids showed increased expression of six cGAS-STING pathway genes, while two were increased for MCF7-J cybrids. In summary, the ARPE19-H and ARPE19-J cybrids behave differentially from each other with or without cisplatin. In contrast, the MCF7-H and MCF7-J cybrids had identical metabolic/bioenergetic profiles and cisplatin responses. Our findings suggest that cancer cell nuclei might have a diminished ability to respond to the modulating signaling of the mtDNA that occurs via the cGAS-STING pathway.


  • North Carolina Macular Dystrophy: Long-term Follow-up of the Original Family

    by Kent W. Small, Robert Wiggins, Nitin Udar, Rosemary Silva-Garcia, Jessica Avetisjan, Andrea Vincent, Fadi S. Shaya


  • Open Access

    Corneal oxidative damage in keratoconus cells due to decreased oxidant elimination from modified expression levels of SOD enzymes, PRDX6, SCARA3, CPSF3, and FOXM1

    by Cristina Kenney, Shari R Atilano, Daniel H Lee, Paula S Fukuhara, Marilyn Chwa, Anthony B Nesburn, Nitin Udar

    Purpose: To compare the levels of gene expression for enzymes involved in production and elimination of reactive oxygen/nitrogen species (ROS/RNS) in normal human corneal cells (NL cells) with those in human corneal cells with keratoconus (KC cells) in vitro. Methods: Primary NL and KC stromal fibroblast cultures were incubated with apocynin (an inhibitor of NADPH oxidase) or N-nitro-L-arginine (N-LLA; an inhibitor of nitric oxide synthase). ROS/RNS levels were measured using an H2DCFDA fluorescent assay. The RT2 Profiler™ PCR Array for Oxidative Stress and Antioxidant Defense was used for initial screening of the NL and KC cultures. Transcription levels for genes related to production or elimination of ROS/RNS were analyzed using quantitative PCR. Immunohistochemistry was performed on 10 intact human corneas using antibodies against SCARA3 and CPSF3. Results: Array screening of 84 antioxidant-related genes identified 12 genes that were differentially expressed between NL and KC cultures. Compared with NL cells, quantitative PCR showed that KC cells had decreased expression of antioxidant genes SCARA3 isoform 2 (0.59-fold, P = 0.02) and FOXM1 isoform 1 (0.61-fold, P = 0.03). KC cells also had downregulation of the antioxidant genes SOD1 (0.4-fold, P = 0.0001) and SOD3 (0.37-fold, P = 0.02) but increased expression of SOD2 (3.3-fold, P < 0.0001), PRDX6 (1.47-fold, P = 0.01), and CPSF3 (1.44-fold, P = 0.02). Conclusion: The difference in expression of antioxidant enzymes between KC and NL suggests that the oxidative stress imbalances found in KC are caused by defects in ROS/RNS removal rather than increased ROS/RNS production.


  • Open Access

    Pisces: an accurate and versatile variant caller for somatic and germline next-generation sequencing data

    by Tamsen Dunn, Gwenn Berry, Dorothea Emig-Agius, Yu Jiang, Serena Lei, Anita Iyer, Nitin Udar, Han-Yu Chuang, Jeff Hegarty, Michael Dickover, et al.

    Next-generation sequencing technology is transitioning quickly from research labs to clinical settings. The diagnosis and treatment selection for many acquired and autosomal conditions necessitate a method for accurately detecting somatic and germline variants. We have developed Pisces, a rapid, versatile and accurate small-variant calling suite designed for somatic and germline amplicon sequencing applications. Accuracy is achieved by four distinct modules, each incorporating a number of novel algorithmic strategies. Pisces is distributed under an open source license and can be downloaded from https://github.com/Illumina/Pisces. Pisces is available on the BaseSpace™ SequenceHub. It is distributed on Illumina sequencing platforms such as the MiSeq™ and is included in the Praxis™ Extended RAS Panel test which was recently approved by the FDA. Supplementary data are available at Bioinformatics online.


  • Open Access

    Role of STING complex in differential retrograde signaling in cybrids with K versus H haplogroup mtDNA

    by Kevin Schneider, Marilyn Chwa, Shari R. Atilano, Sonali Nashine, Nitin Udar, David S. Boyer, S. Michal Jazwinski, Michael V. Miceli, Anthony B. Nesburn, Baruch D. Kuppermann, et al.

    Mitochondrial (mt) DNA haplogroups, defined by specific single nucleotide polymorphism (SNPs) patterns, represent populations of diverse geographic origins and may play a role in disparate disease susceptibilities found in different ethnic/racial populations. The most common European haplogroup is H, while the K haplogroup is highly associated with Ashkenazi Jewish populations. Studies using transmitochondrial cybrids (cell lines with identical nuclei but mitochondria from either H or K haplogroup subjects) demonstrated significant molecular and biological differences but mechanisms for these disparities are unclear. In this study, we hypothesized that there is differential retrograde signaling occurring between the Stimulator of Interferon Genes (STING) pathway and H versus K mtDNA haplogroups. Results showed that K cybrids exhibit increased levels of cytoplasmic mtDNA fragments. After STING Knock-Down, H cybrids had lower expression levels for EGFR, BRCA1, DNMT3A , DNMT3B, HDAC1, and IFNα genes, but upregulated DNMT3A compared to control H cybrids. The STING-KD K cybrids showed downregulation of EGFR, DNMT3A, HDAC1, HCAD9, CFH , and CHI, along with upregulation of DNMT1 and IL-6 compared to control K cybrids. Since all cybrids have identical nuclei, the STING DNA sensor system interacts differently with K haplogroup mtDNA compared to H mtDNA for genes related to cancer ( EGFR, BRCA1 ), methylation ( DNMT1, DNMT3A, DNMT3B ), acetylation ( HDAC1, HDCA9 ), complement ( CFH, CHI ) and inflammation ( IFNα, IL-6 ). In summary, in non-pathologic conditions, (a) STING is an important retrograde signaling mechanism(s) and (b) cybrids possessing Ashkenazi Jewish mtDNA (K haplogroup) interact with the STING complex differently compared to H cybrids which affects various disease-related pathways.

  • Open Access

    Clinical validation of the next-generation sequencing-based Extended RAS Panel assay using metastatic colorectal cancer patient samples from the phase 3 PRIME study

    by Nitin Udar, Catherine Lofton-Day, Jun Dong, Darcy Vavrek, A. Scott Jung, Kristen Meier, Anita Iyer, Ryan Slaughter, Karen Gutekunst, Bruce A. Bach, et al.

    Purpose To validate a next-generation sequencing (NGS)-based companion diagnostic using the MiSeqDx® sequencing instrument to simultaneously detect 56 RAS mutations in DNA extracted from formalin-fixed paraffin-embedded metastatic colorectal cancer (mCRC) tumor samples from the PRIME study. The test’s ability to identify patients with mCRC likely to benefit from panitumumab treatment was assessed. Methods Samples from PRIME, which compared first-line panitumumab + FOLFOX4 with FOLFOX4, were processed according to predefined criteria using a multiplex assay that included input DNA qualification, library preparation, sequencing, and the bioinformatics reporting pipeline. NGS mutational analysis of KRAS and NRAS exons 2, 3, and 4 was performed and compared with Sanger sequencing. Results In 441 samples, positive percent agreement of the Extended RAS Panel with Sanger sequencing was 98.7% and negative percent agreement was 97.6%. For clinical validation (n = 528), progression-free survival (PFS) and overall survival (OS) were compared between patients with RAS mutations (RAS Positive) and those without (RAS Negative). Panitumumab + FOLFOX4 improved PFS in RAS Negative patients (P = 0.02). Quantitative interaction testing indicated the treatment effect (measured by the hazard ratio of panitumumab + FOLFOX4 versus FOLFOX4) differed for RAS Negative versus RAS Positive for PFS (P = 0.0038) and OS (P = 0.0323). Conclusions NGS allows for broad, rapid, highly specific analyses of genomic regions. These results support use of the Extended RAS Panel as a companion diagnostic for selecting patients for panitumumab, and utilization is consistent with recent clinical guidelines regarding mCRC RAS testing. Overall, approximately 13% more patients were detected with the Extended RAS Panel versus KRAS exon 2 alone. Clinical trial registry identifier NCT00364013 (ClinicalTrials.gov).


  • Increased expression of ApoE and protection from amyloid-beta toxicity in transmitochondrial cybrids with haplogroup K mtDNA

    by Kunal Thaker, Marilyn Chwa, Shari R. Atilano, Pinar Coskun, Javier Cáceres-Del-Carpio, Nitin Udar, David S. Boyer, S. Michal Jazwinski, Michael V. Miceli, Anthony B. Nesburn, et al.


  • Open Access

    North Carolina Macular Dystrophy Is Caused by Dysregulation of the Retinal Transcription Factor PRDM13

    by Kent W. Small, Adam P. DeLuca, S. Scott Whitmore, Thomas Rosenberg, Rosemary Silva-Garcia, Nitin Udar, Bernard Puech, Charles A. Garcia, Thomas A. Rice, Gerald A. Fishman, et al.